U.S. markets open in 1 hour 28 minutes
  • S&P Futures

    4,379.00
    +30.75 (+0.71%)
     
  • Dow Futures

    34,098.00
    +259.00 (+0.77%)
     
  • Nasdaq Futures

    15,113.00
    +103.50 (+0.69%)
     
  • Russell 2000 Futures

    2,196.20
    +19.40 (+0.89%)
     
  • Crude Oil

    71.15
    +0.86 (+1.22%)
     
  • Gold

    1,768.40
    +4.60 (+0.26%)
     
  • Silver

    22.56
    +0.36 (+1.60%)
     
  • EUR/USD

    1.1747
    +0.0019 (+0.16%)
     
  • 10-Yr Bond

    1.3090
    0.0000 (0.00%)
     
  • Vix

    23.17
    +2.36 (+11.34%)
     
  • GBP/USD

    1.3679
    +0.0019 (+0.14%)
     
  • USD/JPY

    109.4150
    -0.0050 (-0.00%)
     
  • BTC-USD

    43,304.28
    -451.69 (-1.03%)
     
  • CMC Crypto 200

    1,085.58
    -48.81 (-4.30%)
     
  • FTSE 100

    6,985.47
    +81.56 (+1.18%)
     
  • Nikkei 225

    29,839.71
    -660.34 (-2.17%)
     

Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

We expect investors to focus on Vaxart, Inc.’s VXRT development efforts for its pipeline candidates when it reports second-quarter 2021 results.

The company has a disappointing earnings surprise history, having missed expectations in three of the trailing four quarters, while beating in one. The average four-quarter negative earnings surprise was 40.7%. In the last reported quarter, Vaxart delivered a negative earnings surprise of 40%.

The stock has rallied 42.6% this year so far against the industry‘s decline of 9.8%.

Zacks Investment Research
Zacks Investment Research


Image Source: Zacks Investment Research

Let’s see how things have shaped up for this announcement.

Factors to Consider

Apart from royalty revenues, Vaxart has no other sources of revenues. The Zacks Consensus Estimate for sales for second-quarter 2021 is $0.55 million.

With no approved product in its portfolio, pipeline development should have remained the key focus for Vaxart in the second quarter, especially the updates on its oral vaccine candidates for COVID-19.

COVID-19 Vaccine

In May, Vaxart announced that it plans to initiate phase II study on its oral COVID-19 vaccine candidate, VXA-CoV2-1, in mid-2021, following positive data from phase I study. The company also announced that the candidate induced higher CD8+ T-cell responses than Pfizer PFE and Moderna’s vaccines in a comparative study. The study also demonstrated VXA-CoV2-1 to be potentially cross-reactive against other strains of COVID-19.

Vaxart plans to start several clinical and pre-clinical studies on its COVID-19 vaccine candidateto develop its multivariant COVID-19 vaccine candidate portfolio. The company is also planning to advance two spike protein-only constructs into phase I/II targeting different COVID-19 variants. The company also plans for boosting studies with previously vaccinated or infected subjects in second half of 2021. An update on all these plans is expected at the second quarter conference call.

Norovirus Vaccine

Considering the serious ailment caused by norovirus, Vaxart plans to initiate four clinical studies in 2021 for its oral norovirus vaccine candidate. The studies will involve evaluation of safety, tolerability, immunogenicity, and efficacy of two-dose vaccination schedule. Vaxart has already initiated three clinical studies in first-half 2021 and anticipates to initiate the fourth clinical study in second-half 2021. An update is expected at the call.

Other Developments

We also inform investors that Vaxart out-licensed its patented antiviral Vapendavir to Altesa Biosciences for milestone payments up to $130 million and royalties for global Vapendavir sales.

We expect the company to discuss the development path forward and progress of its coronavirus vaccine candidate on the second-quarter earnings call.

Earnings Whispers

Our proven model does not conclusively predict an earnings beat for Vaxart this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. Unfortunately, that is not the case here as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.

Earnings ESP: It has an Earnings ESP of -0.58%.

Zacks Rank: Vaxart currently carries a Zacks Rank #3

Stocks to Consider

Here are some other biotech stocks that have the right combination of elements to beat on earnings this time around:

Catalent CTLT has an Earnings ESP of +4.61% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

Ironwood Pharmaceuticals IRWD has an Earnings ESP of +11.11% and a Zacks Rank #2.

VAXART, INC. Price

VAXART, INC. Price
VAXART, INC. Price

VAXART, INC. price | VAXART, INC. Quote


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Ironwood Pharmaceuticals, Inc. (IRWD) : Free Stock Analysis Report

Pfizer Inc. (PFE) : Free Stock Analysis Report

Catalent, Inc. (CTLT) : Free Stock Analysis Report

VAXART, INC. (VXRT) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research